Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma.

Trial Profile

A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer
  • Focus Therapeutic Use
  • Acronyms CORUS
  • Sponsors Eurofarma

Most Recent Events

  • 11 Jul 2014 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
  • 03 May 2013 Actual initiation date changed from Jul 2011 to Jan 2011 as reported by ClinicalTrials.gov.
  • 03 May 2013 Planned End Date changed from 1 Jul 2012 to 1 Dec 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top